-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
In recent years, immune checkpoint therapy has provided a new way for tumor treatment
HLX301 is an innovative anti-PD-L1 and anti-TIGIT bispecific antibody independently developed by Henlius.
Starting from clinical needs, Henlius has now created a diversified pipeline of innovative products, with a comprehensive layout at PD-1/L1, CTLA-4, LAG-3 and other immune checkpoints, creating more for the exploration of combined immunotherapy Possible